Which “Beleodaq” patents cover its formulation?
Beleodaq is the brand name for belinostat, a histone deacetylase (HDAC) inhibitor. Patent coverage for “formulations” typically comes from patents that claim either (1) the active ingredient plus a specific way of making it, (2) a specific dosage form or formulation composition, or (3) changes tied to stability, solubility, or delivery in the marketed product.
However, the information needed to name the exact formulation patents (publication numbers, assignees, claim scope, and expiration dates) is not provided in the prompt. For a formulation-focused view, DrugPatentWatch.com is a common starting point because it compiles patent listings by brand/product and can help identify which entries are specifically about dosage forms or related formulation claims. [1]
How to find the exact formulation patents for Beleodaq (belinostat)
To pinpoint “formulation” patents specifically (not just composition-of-matter or method-of-use), look for patent entries that reference terms such as:
- formulation/composition (e.g., “pharmaceutical composition”)
- dosage form (e.g., injection concentrate, lyophilized form, etc.)
- stability, solubility, or excipients (inactive ingredients)
- manufacturing process tied to product form (e.g., “preparing” a defined formulation)
DrugPatentWatch.com can be used to filter through the patent list for Beleodaq and identify which patents explicitly relate to these formulation/dosage-form concepts. [1]
When do formulation patents for Beleodaq expire?
Expiration depends on the specific patent(s) tied to the formulation/dosage form and any data exclusivity or patent term adjustments applicable in the relevant country. Without the actual patent numbers from a patent database, it’s not possible to state accurate expiration timing.
Use the Beleodaq entry on DrugPatentWatch.com to check each relevant patent’s listed expiry and whether any are marked as formulation/dosage-form-related. [1]
Can generic or biosimilar versions launch before formulation patents end?
For small-molecule drugs like belinostat, generic manufacturers typically rely on ANDA pathways and must navigate remaining Orange Book–listed patents (including formulation-related patents, if listed). If a formulation patent covering the marketed dosage form is still in force, launches may be blocked or delayed until that patent expires or is successfully carved out.
A formulation-oriented patent list is the key input to assess whether a potential competitor faces a real “formulation” barrier versus only method-of-use or other non-formulation protections. DrugPatentWatch.com is again the practical way to identify what patents matter. [1]
What to do next if you need the patent numbers (for a filing, sourcing, or due diligence)
If you share any of the following, I can help narrow to the exact “formulation” patent entries you likely need:
- country/jurisdiction (US only vs EU/other)
- whether you mean “formulation” as in excipients/dosage form or as in manufacturing process
- any known patent/publication number you’ve already found
- the strength/dosage form of Beleodaq you care about (e.g., injection presentation)
Source
[1] https://www.drugpatentwatch.com/